StemCell Institute () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

GNI Group Ltd.

OncoTherapy Science, Inc.

Cyfuse Biomedical KK

MEDINET Co., Ltd.

SUSMED, Inc.

Stella Pharma Corp.

Oncolys BioPharma, Inc.

Chiome Bioscience, Inc.

StemCell Institute

Peptidream, Inc.

Carna Biosciences, Inc.

Why is StemCell Institute ?

PRE-TAX PROFIT(Q) At JPY 67.45 MM has Fallen at -52.31%
ROCE(HY) Lowest at 9.23%
DEBTORS TURNOVER RATIO(HY) Lowest at 1.46%

With ROE of 14.68%, it has a very attractive valuation with a 4.04 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -41.27%, its profits have risen by 24.5% ; the PEG ratio of the company is 1.1

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -41.27% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is StemCell Institute for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

StemCell Institute

-41.27%

-1.13

47.05%

Japan Nikkei 225

27.37%

1.06

25.71%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

14.56%

EBIT Growth (5y)

22.63%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.91

Tax Ratio

31.80%

Dividend Payout Ratio

66.37%

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

10.52%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.04

EV to EBIT

18.92

EV to EBITDA

14.48

EV to Capital Employed

-116.15

EV to Sales

2.96

PEG Ratio

1.12

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

14.68%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

NET SALES(Q)

Highest at JPY 700.99 MM

-30What is not working for the Company

PRE-TAX PROFIT(Q)

At JPY 67.45 MM has Fallen at -52.31%

ROCE(HY)

Lowest at 9.23%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.46%

INTEREST COVERAGE RATIO(Q)

Lowest at 7,280.85

DEBT-EQUITY RATIO (HY)

Highest at -83.33 %

INTEREST(Q)

Highest at JPY 1.36 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 14.1 %

NET PROFIT(Q)

Lowest at JPY 43.1 MM

EPS(Q)

Lowest at JPY 4.24

Here's what is working for StemCell Institute

Net Sales

Highest at JPY 700.99 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Here's what is not working for StemCell Institute

Pre-Tax Profit

At JPY 67.45 MM has Fallen at -52.31%

over average net sales of the previous four periods of JPY 141.43 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Interest

At JPY 1.36 MM has Grown at 29.83%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest Coverage Ratio

Lowest at 7,280.85

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Profit

At JPY 43.1 MM has Fallen at -55.31%

over average net sales of the previous four periods of JPY 96.45 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Debtors Turnover Ratio

Lowest at 1.46% and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Interest

Highest at JPY 1.36 MM

in the last five periods and Increased by 29.83% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Operating Profit Margin

Lowest at 14.1 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Net Profit

Lowest at JPY 43.1 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

EPS

Lowest at JPY 4.24

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (JPY)

Debt-Equity Ratio

Highest at -83.33 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio